Outcomes of a National Institute of Allergy and Infectious Diseases Workshop on Understanding HIV-Exposed but Seronegative Individuals

被引:0
|
作者
Young, Janet M. [1 ]
Turpin, Jim A. [2 ]
Musib, Runa [3 ]
Sharma, Opendra K. [1 ]
机构
[1] NIAID, Pathogenesis & Basic Res Branch, Basic Sci Program, Div Aids,NIH,HHS, Bethesda, MD 20892 USA
[2] NIAID, Microbicide Res Branch, Prevent Sci Program, Div Aids,NIH,HHS, Bethesda, MD 20892 USA
[3] NIAID, Henry M Jackson Fdn Advancement Mil Med, Contractor Vaccine Res Program, Div Aids,NIH,HHS, Bethesda, MD 20892 USA
关键词
HUMAN-IMMUNODEFICIENCY-VIRUS; HOMOSEXUAL-MEN; IN-VIVO; RESISTANCE; TYPE-1; EXPRESSION; CHILDREN; RISK;
D O I
10.1089/aid.2010.0313
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The fascinating conundrum that some individuals who are exposed to HIV in ways that would make viral transmission highly likely, yet are able to remain uninfected, has been appreciated for many years. As early as the late 1980s, reports of such individuals began appearing in the HIV/AIDS literature. Despite the critical importance of understanding possible mechanisms of natural HIV resistance for developing effective prevention strategies, numerous obstacles have prevented this essential area of scientific exploration from moving forward. The Workshop held on July 8-9, 2010 and supported by the Office of AIDS Research (OAR), the National Institute of Allergy and Infectious Diseases (NIAID), and the National Institute on Drug Abuse (NIDA) at the NIH hosted 200 participants and utilized the expertise of 42 AIDS researchers as invited speakers, session chairs, and discussion leaders for presentations and breakout sessions in an attempt to remove some of those obstacles. Accomplishments of the participants included developing a consensus for a new general term for the field, HIV-exposed seronegative (HESN), while recognizing the necessity to identify and utilize secondary descriptive criteria such as exposure level, risk group, duration of seronegativity, or natural resistance. Three key questions for future research were also identified by the group: (1) What is different in HESN versus those who get infected? (2) What is the immune response in HESN and is it just a marker of exposure or a correlate of protection? (3) What are the HESN host factors that help HESN resist infection? This report briefly summarizes the presentations, and describes future directions for addressing these questions and challenges.
引用
收藏
页码:737 / 743
页数:7
相关论文
共 50 条
  • [1] Understanding the "lucky few": The conundrum of HIV-exposed, seronegative individuals
    Shacklett B.L.
    [J]. Current Infectious Disease Reports, 2006, 8 (3) : 248 - 253
  • [2] Understanding the "lucky few": The conundrum of HIV-exposed, seronegative individuals
    Shacklett B.L.
    [J]. Current HIV/AIDS Reports, 2006, 3 (1) : 26 - 31
  • [3] Mucosal immunoglobulin A in HIV-exposed seronegative individuals
    Trabattoni, Daria
    Biasin, Mara
    Clerici, Mario
    [J]. AIDS, 2012, 26 (17) : 2247 - 2250
  • [4] Pharmacogenomics of HIV Therapy: Summary of a Workshop Sponsored by the National Institute of Allergy and Infectious Diseases
    Haas, David W.
    Kuritzkes, Daniel R.
    Ritchie, Marylyn D.
    Amur, Shashi
    Gage, Brian F.
    Maartens, Gary
    Masys, Dan
    Fellay, Jacques
    Phillips, Elizabeth
    Ribaudo, Heather J.
    Freedberg, Kenneth A.
    Petropoulos, Christos
    Manolio, Teri A.
    Gulick, Roy M.
    Haubrich, Richard
    Kim, Peter
    Dehlinger, Marjorie
    Abebe, Rahel
    Telenti, Amalio
    [J]. HIV CLINICAL TRIALS, 2011, 12 (05): : 277 - 285
  • [5] The 'immunologic advantage' of HIV-exposed seronegative individuals
    Detels, Roger
    [J]. AIDS, 2009, 23 (12) : 1611 - 1611
  • [6] The 'immunologic advantage' of HIV-exposed seronegative individuals
    Miyazawa, Masaaki
    Lopalco, Lucia
    Mazzotta, Francesco
    Lo Caputo, Sergio
    Veas, Francisco
    Clerici, Mario
    [J]. AIDS, 2009, 23 (02) : 161 - 175
  • [7] Report from the National Institute of Allergy and Infectious Diseases workshop on drug allergy
    Wheatley, Lisa M.
    Plaut, Marshall
    Schwaninger, Julie M.
    Banerji, Aleena
    Castells, Mariana
    Finkelman, Fred D.
    Gleich, Gerald J.
    Guttman-Yassky, Emma
    Mallal, Simon A. K.
    Naisbitt, Dean J.
    Ostrov, David A.
    Phillips, Elizabeth J.
    Pichler, Werner J.
    Platts-Mills, Thomas A. E.
    Roujeau, Jean-Claude
    Schwartz, Lawrence B.
    Trepanier, Lauren A.
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2015, 136 (02) : 262 - +
  • [8] Mucosal and systemic immune activation in HIV-exposed seronegative individuals
    Clerici, M
    [J]. RETROVIRUSES OF HUMAN AIDS AND RELATED ANIMAL DISEASES, 2000, : 43 - 45
  • [9] The 'immunologic advantages' of HIV-exposed seronegative individuals: authors' reply
    Miyazawa, Masaaki
    Clerici, Mario
    [J]. AIDS, 2009, 23 (12) : 1612 - 1612
  • [10] Identification of a Specific miRNA Profile in HIV-Exposed Seronegative Individuals
    Yahyaei, Sara
    Biasin, Mara
    Saulle, Irma
    Gnudi, Federica
    De Luca, Mariacristina
    Tasca, Karen I.
    Trabattoni, Daria
    Lo Caputo, Sergio
    Mazzotta, Francesco
    Clerici, Mario
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2016, 73 (01) : 11 - 19